Piper Sandler Maintains Overweight on Praxis Precision Medicine, Maintains $270 Price Target
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Yasmeen Rahimi maintains an Overweight rating on Praxis Precision Medicine (NASDAQ:PRAX) with a $270 price target.
July 01, 2024 | 1:50 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Piper Sandler analyst Yasmeen Rahimi maintains an Overweight rating on Praxis Precision Medicine with a $270 price target, indicating strong confidence in the company's future performance.
The reaffirmation of an Overweight rating and a high price target of $270 by a reputable analyst suggests strong confidence in Praxis Precision Medicine's future performance. This is likely to positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100